In a landmark discovery that resolves a biological enigma spanning more than three decades, researchers at the Memorial Sloan Kettering Cancer Center (MSK) have identified a crucial, previously misunderstood mechanism of the human immune system. The study, published October 7 in the journal Nature, reveals that a specific chemical signal—long thought to be a simple "alarm" to summon immune cells to sites of infection—actually performs a dual role: it also serves as a protective shield, preventing the body’s own defensive fire from incinerating healthy tissue.
This breakthrough not only solves a mystery dating back to 1992 but also opens new vistas for treating inflammatory bowel disease (IBD), asthma, and various forms of cancer. By identifying the elusive gene responsible for this mechanism, the team has effectively provided a roadmap for future therapies that could modulate, rather than simply suppress, the body’s inflammatory response.
The Origins of a Biological Mystery
The story begins in 1992 at McGill University, where scientists first encountered a mysterious fatty signaling molecule known as 5-oxoETE (5-oxo-6,8,11,14-eicosatetraenoic acid). Researchers observed that this molecule functioned as a chemical beacon, directing white blood cells—the body’s "first responders"—toward sites of infection or injury.
Central to this process was an enzyme that could both synthesize and degrade 5-oxoETE. However, while the enzyme’s chemical function was clear, its genetic origin remained a "ghost" in the biological machine. For over 30 years, the inability to identify the specific gene producing this enzyme left scientists unable to manipulate the pathway in controlled experiments. Without this genetic key, researchers were left with a descriptive name for a protein they could not fully characterize, creating a significant roadblock in immunology.
A Pivot to the Zebrafish: Breaking the Mouse Model Paradigm
The breakthrough at MSK was made possible by a departure from conventional research standards. While mice and rats account for the vast majority of biomedical models due to their 80% genetic overlap with humans, they proved fundamentally inadequate for this particular puzzle.
"Mice and rats are the primary model used in biomedical research," explains Dr. Yanan Ma, a postdoctoral researcher and recipient of the 2023 Marie-Josée Kravis WISE Fellowship. "It makes sense because they are mammals. However, they lack a known immune cell receptor capable of recognizing 5-oxoETE."
Because the signaling pathway is effectively "broken" or absent in rodents, the MSK team turned to the zebrafish. Zebrafish, as it turns out, have retained the necessary biological machinery, providing a clear window into how the 5-oxoETE pathway functions in a living organism. By utilizing this model, Dr. Ma and her colleagues were able to systematically screen genes, eventually identifying DHRS7 as the long-sought gene responsible for the mystery enzyme. When the DHRS7 gene was disabled, the enzyme ceased to function, confirming that the decades-long search had finally concluded.
The Paradox of Inflammation
The discovery reached a turning point when Dr. Ma’s work intersected with that of Dr. Miklos Lengyel, who was researching colitis in the same laboratory. While Dr. Ma was identifying the gene, Dr. Lengyel was observing a counter-intuitive phenomenon in zebrafish models.
In theory, removing the receptor for an inflammatory signal (the 5-oxoETE receptor, known as OXER1 in humans or hcar1-4 in zebrafish) should reduce inflammation by preventing immune cells from receiving the "attack" signal. However, when the researchers disabled the receptor, the opposite occurred: the zebrafish developed severe, spontaneous intestinal inflammation.
"It made absolutely no sense," Dr. Lengyel recalls. "If you remove the receptor that detects the inflammatory signal, you would expect less inflammation, not more."
This unexpected result forced the team to rethink their understanding of the immune response. They discovered that the 5-oxoETE pathway was not merely an "on-switch" for inflammation; it was a complex regulatory system. By removing the pathway, the researchers had stripped the gut of a vital protective mechanism, leaving healthy cells vulnerable to the very substances immune cells use to fight off pathogens.
The Immune System as a "Shield"
The study reveals that the 5-oxoETE pathway triggers the production of NUDIX hydrolases—a group of enzymes that act as a cellular maintenance crew. These enzymes clear out damaged DNA building blocks that accumulate during the metabolic stress of an immune attack.
When the 5-oxoETE pathway is functioning correctly, it alerts the immune system to danger while simultaneously "armoring" neighboring healthy cells against collateral damage. When this pathway is disabled, the healthy cells are defenseless against the oxidative stress generated by immune activity.
"As it turns out, this signal isn’t just an alarm, it’s also a shield," says Dr. Philipp Niethammer, the lead cell biologist of the laboratory. "These immune cells unleash chemical warfare against a pathogen, and organisms have evolved an elegant way of protecting healthy cells at the same time."
Implications for Modern Medicine
The implications of this discovery are vast, particularly for diseases characterized by chronic, uncontrolled inflammation. In conditions like IBD, asthma, and certain gastrointestinal cancers, the 5-oxoETE pathway is often disrupted.
Potential Therapeutic Applications
- Cancer Treatment: Research has shown that mutations affecting DHRS7 and OXER1 correlate with poor outcomes in colorectal, pancreatic, and kidney cancers. By activating this pathway, scientists might one day increase the gut’s resilience to the harsh side effects of chemotherapy and radiation therapy.
- Inflammatory Bowel Disease (IBD): Patients with IBD often show lower concentrations of 5-oxoETE. Restoring or bolstering this signaling could provide a new therapeutic strategy to prevent tissue damage during flare-ups.
- Respiratory Health: Evidence from primate studies suggests that blocking this pathway in the lungs causes the loss of protective, mucus-producing cells, suggesting that current anti-inflammatory drugs might inadvertently be removing a protective barrier.
The research suggests that future treatments should focus on "precision modulation"—strengthening the protective arm of the immune system without compromising the body’s ability to fight off genuine infections.
Integrating Mechanical and Metabolic Stress
The scope of the discovery is further broadened by the work of doctoral student Zaza Gelashvili, whose research focuses on how cells detect physical mechanical forces. His work, published in Nature Communications earlier in 2026, illustrates that the body integrates mechanical injury signals with metabolic signals to create a unified response.
"Physical stress unlocks the raw material, oxidative stress drives the conversion, and DHRS7 amplifies the signal," Gelashvili explains. This hierarchy suggests that the body is far more sophisticated at assessing "danger" than previously believed, utilizing a multi-layered system that distinguishes between an invading bacterium and a mechanical scrape, all while maintaining the integrity of healthy tissue.
A Collaborative Scientific Achievement
Dr. Niethammer notes that the publication is unique because it combines two distinct, major projects into one cohesive finding. "Typically, when you have a paper with two first authors, there is just one story that two people contributed to equally," he says. "But in this paper, there are two separate projects led by two different authors that came together as one larger discovery."
The project, supported by the National Institutes of Health, the Starr Foundation, and the MSK Cancer Center, stands as a testament to the power of basic research. By diving into the fundamental biology of a zebrafish, the team has provided a new framework for understanding how we can live alongside our own immune defenses without being destroyed by them. As the medical community digests these findings, the focus will now shift to clinical trials and the development of small-molecule drugs that can mimic or enhance this newly discovered biological shield.
